Ignite Creation Date:
2025-12-24 @ 3:37 PM
Ignite Modification Date:
2026-01-29 @ 8:04 PM
Study NCT ID:
NCT02521792
Status:
TERMINATED
Last Update Posted:
2020-10-19
First Post:
2015-08-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects
Sponsor:
Clementia Pharmaceuticals Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Fibrodysplasia Ossificans Progressiva | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Open-label study | View |
| None | Clinical trial Phase 2 | View |
| None | Efficacy and safety | View |
| None | Heterotopic ossification | View |
| None | Fibrodysplasia Ossificans Progressiva | View |
| None | Flare-up | View |
| None | Palovarotene | View |
| None | Retinoic acid receptor agonist | View |
| None | Retinoic acid receptor gamma agonist | View |
| None | Clementia | View |
| None | Myositis Ossificans Progressiva | View |
| None | Munchmeyer's Disease | View |
| None | FOP | View |